Emmanuelle Ferrant - Concepedia

Author

Emmanuelle Ferrant

Also Known As

E Ferrant, E, Ferrant, E. Ferrant, Emmanuel Ferrant, Emmanuelle FERRANT, Emmanuelle Ferrant, Enrico Ferrant, Ferrant E, Ferrant, E., Ferrant, Emmanuelle

112

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Hôpital Lyon Sud Hospices Civils de Lyon Inserm Université Claude Bernard Lyon 1 CHU Dijon Bourgogne

About

Emmanuelle Ferrant is an author at Hôpital Lyon Sud specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	673
2	Health Sciences	4	4	108
3	Public Health	1	1	56
4	Cell Biology	1	1	19
5	Cellular Therapies	1	1	130

Emmanuelle Ferrant

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib David Ghez, Anne Calleja, Caroline Protin, Blood	2018	288
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma Salim Kanoun, Cédric Rossi, Alina Berriolo-Riedinger, European Journal of Nuclear Medicine and Molecular Imaging Tumor BiologyLymphoid NeoplasiaHodgkin LymphomaMedicinePathology	2014	175
The Reversed Halo Sign: Pathognomonic Pattern of Pulmonary Mucormycosis in Leukemic Patients With Neutropenia? C. Legouge, Denis Caillot, Marie‐Lorraine Chrétien, Clinical Infectious Diseases	2013	167
Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, American Journal of Hematology Cell TherapyImmunologyImmunoeditingPathologyImmunotherapeutics	2020	130
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells Pierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, Clinical Nuclear Medicine	2021	78
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified Estelle Bourbon, Delphine Maucort‐Boulch, Juliette Fontaine, Blood Advances	2021	61
Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study François Girodon, Gilles Bonicelli, Céline Schaeffer, Haematologica Essential ThrombocythemiaDiagnosisPathologyJak2 Mutation ScreeningApparent Incidence	2009	56
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Blood	2023	48
Evolution of procalcitonin, C‐reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis Marjorie Roques, Marie Lorraine Chrétien, Camille Favennec, Mycoses Diagnostic MycologyFungal Cell BiologyImmunodeficienciesImmunologyLeukaemia Patients	2016	36

Page 1